Co-Founder Resigns from InspireMD Board

Campbell Rogers, M.D., has become Boston, Mass.-based InspireMD Inc.’s newest board member. Rogers currently serves as chief medical officer of HeartFlow Inc., a cardiovascular diagnostics company based in Redwood City, Calif.

“Dr. Rogers has incredible experience with and insight into this industry,” said Sol Barer, Ph.D., chairman of the board at InspireMD. “We are extremely pleased to welcome him to our Board of Directors and are confident he will be a great addition. Dr. Rogers brings a wealth of knowledge with vast clinical, academic and industry experience that will be instrumental to our company as we continue to grow. We intend to leverage his expertise and strategic vision as we continue to establish ourselves as a leader in the stent market while delivering value to our shareholders.”

Prior to joining HeartFlow, Rogers was the chief scientific officer and global head of research and development, a role created specifically for him, at Cordis Corporation, a Johnson & Johnson company. Before Cordis, he was an associate professor of medicine and director of the Cardiac Catheterization Laboratory at Harvard Medical School, Brigham and Women’s Hospital in Boston. Rogers has also served as principal investigator for numerous interventional cardiology devices, diagnostic and pharmacology trials and is well published in the cardiovascular disease space. Along with his publications, he has also been the recipient of numerous research grant awards from the National Institute of Health and American Heart Association.

Rogers is taking the place of Ofir Paz, a co-founder and former CEO of InspireMD, who resigned from the board. In a statement, Barere thanked Paz for his leadership and credited his “hard work and dedication” for helpingbring the company to where it is today.

InspireMD makes embolic protection stents. Its key product is the MGuard EPS, which along with an integrated micro mesh net, is designed to prevent clots formed during heart attacks from breaking off and causing further blockages in the bloodstream.